$ABBV news and market catalysts

AbbVie Receives European Commission Approval Of RINVOQ For Children With Active Polyarticular Juvenile Idiopathic Arthritis Aged Two And Older

AbbVie Enters Multi-Year Collaboration With Iambic To Accelerate Discovery And Development Of Small Molecule Therapies Across Immunology, Neuroscience And Oncology; Iambic To Receive Upfront Payment And Is Eligible For Milestone Payments And Tiered Royalties

AbbVie Says Real-World Studies Show VRAYLAR Improved Depressive Symptoms In Bipolar I Depression, Adjunctive Major Depressive Disorder At Psych Congress 2026

AbbVie Exec Says Plans To Start Enrolling Apogee's Zumilokibart This Year, Targets Launch In Early 2030; Says Will Present Late-stage Data For Blood Cancer Drug Etentamig At International Myeloma Society Meeting Later In September

What's Going On With AbbVie Stock Friday?

AbbVie Drug Shows Significant Reductions in Menstrual Migraine Days

HSBC Maintains Buy on AbbVie, Raises Price Target to $315

AbbVie Announces Topline Results From Its Phase 3 LUNA Study Of Atogepant For Preventive Treatment Of Menstrual Migraine In Adults; Atogepant Demonstrated Statistically Significant Reductions In Migraine Days Associated With Menstrual Period, Meeting Primary And All Eight Ranked Secondary Endpoints Versus Placebo

AbbVie Touts Positive Data For Multiple Myeloma Drug

Abbvie Announces Topline Results From The Phase 3 Cervino Trial Showing Etentamig Significantly Improved Response Rate And Progression-Free Survival In Patients With Relapsed/Refractory Multiple Myeloma; Etentamig Achieves 74% Orr And 60% Risk Reduction In Phase 3 Cervino Trial; Etentamig Demonstrates Low Rates Of Cytokine Release Syndrome And Fatal Infections; Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results To Be Presented Sept 23-26

AbbVie To Present New Data From Its ABBV-1480 PD-1/VEGF Bispecific Antibody In Frontline Non-Small Cell Lung Cancer At 2026 World Conference On Lung Cancer

Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $303

Wolfe Research Upgrades AbbVie to Outperform, Announces $300 Price Target

BNP Paribas Maintains Neutral on AbbVie, Raises Price Target to $247

'AbbVie Seeks at Least $8 Billion in Debt to Fund Apogee Deal' - Bloomberg

AbbVie's Allergan Aesthetics Receives FDA Acceptance For Review For Its Supplemental Biologics License Application For BOTOX Cosmetic

Guggenheim Maintains Buy on AbbVie, Raises Price Target to $288

Canaccord Genuity Maintains Buy on AbbVie, Raises Price Target to $290

Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $285

Conference Call: AbbVie Sees Q3 Adj EPS $3.84-$3.88 vs $3.84 Est; Sees Sales $17.200B vs $17.322B Est

AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat

AbbVie Exec Says Now Expect Total Annual Net Revenue Of ~$67.6B, Increase Of $300M Versus Previous Forecast

AbbVie shares are trading lower after the company reported Q2 financial results and lowered its FY26 adjusted EPS guidance below estimates.

AbbVie Lowers FY2026 Adj EPS Guidance from $14.08-$14.28 to $13.87-$14.07 vs $14.08 Est

CORRECTION: AbbVie Lowers FY2026 Adj EPS Guidance from $13.91-$14.11 to $13.87-$14.07 vs $14.08 Est

AbbVie Q2 Adj. EPS $3.65 Beats $3.60 Estimate, Sales $16.990B Beat $16.765B Estimate

Barclays Maintains Overweight on AbbVie, Raises Price Target to $300

AbbVie's RINVOQ Wins European Commission Approval For Non-Segmental Vitiligo, First Systemic Medication Approved In EU For This Condition

CNBC Halftime Report Final Trades: AbbVie, Transocean, Cerebras Systems, Netflix

Allergan Aesthetics' Boey Receives European Commission Approval To Treat Moderate To Severe Lines Between The Eyebrows

UBS Maintains Neutral on AbbVie, Raises Price Target to $260

BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $300